Literature DB >> 20591885

The revised Ghent nosology for the Marfan syndrome.

Bart L Loeys1, Harry C Dietz, Alan C Braverman, Bert L Callewaert, Julie De Backer, Richard B Devereux, Yvonne Hilhorst-Hofstee, Guillaume Jondeau, Laurence Faivre, Dianna M Milewicz, Reed E Pyeritz, Paul D Sponseller, Paul Wordsworth, Anne M De Paepe.   

Abstract

The diagnosis of Marfan syndrome (MFS) relies on defined clinical criteria (Ghent nosology), outlined by international expert opinion to facilitate accurate recognition of this genetic aneurysm syndrome and to improve patient management and counselling. These Ghent criteria, comprising a set of major and minor manifestations in different body systems, have proven to work well since with improving molecular techniques, confirmation of the diagnosis is possible in over 95% of patients. However, concerns with the current nosology are that some of the diagnostic criteria have not been sufficiently validated, are not applicable in children or necessitate expensive and specialised investigations. The recognition of variable clinical expression and the recently extended differential diagnosis further confound accurate diagnostic decision making. Moreover, the diagnosis of MFS--whether or not established correctly--can be stigmatising, hamper career aspirations, restrict life insurance opportunities, and cause psychosocial burden. An international expert panel has established a revised Ghent nosology, which puts more weight on the cardiovascular manifestations and in which aortic root aneurysm and ectopia lentis are the cardinal clinical features. In the absence of any family history, the presence of these two manifestations is sufficient for the unequivocal diagnosis of MFS. In absence of either of these two, the presence of a bonafide FBN1 mutation or a combination of systemic manifestations is required. For the latter a new scoring system has been designed. In this revised nosology, FBN1 testing, although not mandatory, has greater weight in the diagnostic assessment. Special considerations are given to the diagnosis of MFS in children and alternative diagnoses in adults. We anticipate that these new guidelines may delay a definitive diagnosis of MFS but will decrease the risk of premature or misdiagnosis and facilitate worldwide discussion of risk and follow-up/management guidelines.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20591885     DOI: 10.1136/jmg.2009.072785

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  471 in total

1.  Lack of joint hypermobility increases the risk of surgery in adolescent idiopathic scoliosis.

Authors:  Gabe Haller; Hannah Zabriskie; Shelby Spehar; Timothy Kuensting; Xavier Bledsoe; Ali Syed; Christina A Gurnett; Matthew B Dobbs
Journal:  J Pediatr Orthop B       Date:  2018-03       Impact factor: 1.041

Review 2.  Genetics for the general internist.

Authors:  Christina M Laukaitis
Journal:  Am J Med       Date:  2011-11-11       Impact factor: 4.965

Review 3.  CHD associated with syndromic diagnoses: peri-operative risk factors and early outcomes.

Authors:  Benjamin J Landis; David S Cooper; Robert B Hinton
Journal:  Cardiol Young       Date:  2015-09-08       Impact factor: 1.093

4.  Clinical utility gene card for: Hereditary thoracic aortic aneurysm and dissection including next-generation sequencing-based approaches.

Authors:  Mine Arslan-Kirchner; Eloisa Arbustini; Catherine Boileau; Philippe Charron; Anne H Child; Gwenaelle Collod-Beroud; Julie De Backer; Anne De Paepe; Anna Dierking; Laurence Faivre; Sabine Hoffjan; Guillaume Jondeau; Britta Keyser; Bart Loeys; Karin Mayer; Peter N Robinson; Jörg Schmidtke
Journal:  Eur J Hum Genet       Date:  2015-10-28       Impact factor: 4.246

5.  Atypical phenotypes associated with pathogenic CHD7 variants and a proposal for broadening CHARGE syndrome clinical diagnostic criteria.

Authors:  Caitlin L Hale; Adrienne N Niederriter; Glenn E Green; Donna M Martin
Journal:  Am J Med Genet A       Date:  2015-11-21       Impact factor: 2.802

6.  Periosteal osteosarcoma and Marfan's syndrome: A case report and literature review.

Authors:  Guo-Ping Xie; Hui-Juan Song; Nan Jiang; Cheng-He Qin; Lei Wang; Shao-Yong Xu; Bin Yu
Journal:  Oncol Lett       Date:  2015-11-05       Impact factor: 2.967

7.  Ghent Criteria an Aid to Diagnose Latent Systemic Diseases in Marfan Syndrome.

Authors:  Gomathi Ramlingam; Uma Maheswari T Natarajasundaram
Journal:  J Clin Diagn Res       Date:  2015-05-01

8.  Genetic dissection of marfan syndrome and related connective tissue disorders: an update 2012.

Authors:  S Hoffjan
Journal:  Mol Syndromol       Date:  2012-06-12

9.  TGFβRIIb mutations trigger aortic aneurysm pathogenesis by altering transforming growth factor β2 signal transduction.

Authors:  Katharine J Bee; David C Wilkes; Richard B Devereux; Craig T Basson; Cathy J Hatcher
Journal:  Circ Cardiovasc Genet       Date:  2012-10-24

Review 10.  Echocardiographic methods, quality review, and measurement accuracy in a randomized multicenter clinical trial of Marfan syndrome.

Authors:  Elif Seda Selamet Tierney; Jami C Levine; Shan Chen; Timothy J Bradley; Gail D Pearson; Steven D Colan; Lynn A Sleeper; M Jay Campbell; Meryl S Cohen; Julie De Backer; Lin T Guey; Haleh Heydarian; Wyman W Lai; Mark B Lewin; Edward Marcus; Christopher R Mart; Ricardo H Pignatelli; Beth F Printz; Angela M Sharkey; Girish S Shirali; Shubhika Srivastava; Ronald V Lacro
Journal:  J Am Soc Echocardiogr       Date:  2013-04-10       Impact factor: 5.251

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.